U.S. Biosimilars Market 2019 Global Market Revenue, Growth, Top Players, Share, Demand, Trends and Forecasts to 2026

Share this news:

U.S. Biosimilars Market to Expand at 54.7% CAGR; Increasing Demand from the Unmet Populace to Create Growth Opportunities

The U.S. biosimilars market will gain momentum from the increasing government support to adopt biosimilars in the healthcare sectors. The report provides valuable insights into the drivers influencing growth of the market. As per the report, the U.S. biosimilars market is anticipated to report an impressive CAGR of 54.7% during the forecast period. The report also states that the U.S. market was valued at US$ 436.1 Mn in 2018.

Browse Complete Report Details@ https://www.fortunebusinessinsights.com/industry-reports/u-s-biosimilars-market-100990

Increased Research and Development Initiatives to Drive the Market

Biosimilars are the copies of original products. Due to the high cost of pharmaceutical drugs, healthcare facilities are not accessible to people from every economical stratum. This is where biosimilars come to recuse. Being an identical copy, biosimilars help in treating chronic diseases like cancer and arthritis in an effective manner just as original medications do. The market is likely to grow during the forecast period because of an increasing demand from the masses. Also, a rise in research and development initiatives by prominent organizations have increased market opportunities. This has led to tough competition in the U.S. biosimilars market.

Autoimmune Diseases Segment Projected to Dominate the Market in the U.S.

The U.S. biosimilars market is classified into three segments, namely, by distribution channel, by disease indication, and by drug class. By distribution channel, the market is grouped into online pharmacy, hospital pharmacy, and retail pharmacy. In terms of disease indication, the market is divided into cancer and autoimmune diseases such as arthritis, neutropenia, psoriasis, and others.

In 2018, the autoimmune diseases held a market share of 92.0%. The segment is anticipated to remain in the leading position the U.S. biosimilars market during the forecast period. Factors like increasing adoption of biosimilars, rise in the prevalence of autoimmune diseases, and availability of limited drugs are likely to boost the segment. The Centers of Disease Control and Prevention declared that approximately 26% adults are estimated to have arthritis by 2040.

Pfizer Inc., Samsung Bioepis Co. Ltd., and Other Key Players Tend to Focus on Product Launch to Strengthen Position

Samsung Bioepis Co. Ltd, a biopharmaceutical company, received approval from Food and Drugs Administrations for ETICOVO, a biosimilar of Etanercept in April 2019. It is used for the treatment of plaque psoriasis, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, ankylosing spondylitis, and psoriatic arthritis.

Pfizer Inc. a multinational pharmaceutical company based in the U.S., received approval from FDA for TRAZIMERA, a biosimilar referencing Herceptin in March 2019. It will be used to treat gastroesophageal junction adenocarcinoma and breast cancer. Earlier in July 2018, Pfizer Inc. announced that the company has received FDA approval for NIVESTYM.

Get Sample PDF Brochure@ https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/u-s-biosimilars-market-100990

Some of the other players operating in the U.S. biosimilars market are F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck & Co., Celltrion Inc., Coherus BioSciences, Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, and others.

TABLE OF CONTENT:

1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities

4. Key Insights
4.1 Prevalence of Key Disease Associated with the Scope - U.S., 2018
4.2 New Product Launch
4.3 Pipeline Analysis
4.4 Regulatory Scenario
4.5. Reimbursement Scenario
4.6. Patent Snapshot of Biologics
4.6 Key Industry Developments - Partnerships, Mergers & Acquisitions

More Trending Topics from Future Business Insights-

Mass Spectrometer Market Revenue to cross US$ 10,044.7 Mn| 2019 Worldwide Opportunities, Market Share, Key Players

Revenue US$ 722.0 Mn, Ophthalmic Lasers Market| Industry Size, Share and Global Trend

Contact Info:
Name: Mr. Ashwin Arora
Email: Send Email
Organization: Fortune Business Insights Pvt. Ltd.
Website: https://www.fortunebusinessinsights.com/

Release ID: 88912807

CONTACT ISSUER
Name: Mr. Ashwin Arora
Email: Send Email
Organization: Fortune Business Insights Pvt. Ltd.
SUBSCRIBE FOR MORE